It's certainly true that tracking model growth shows more options appearing, but that doesn't mean the tracking itself causes platforms like OpenRouter to expand their offerings.
In practice, merely observing a problem, like rising patient numbers, doesn't create more hospital beds or staff; it just highlights the finite resources.
OpenRouter's leap from 63 to 668 models is likely driven by their own business strategy or market pressures, not just the existence of a report.
We see this constantly with new medications—tracking their development is one thing, but getting them funded and widely available is a completely different, resource-intensive challenge.
Every new addition, whether a model or a medicine, drains attention and liquidity from elsewhere if it doesn't offer a demonstrable, sustainable benefit.